前立腺がん治療薬の世界市場レポート 2025年

前立腺がん治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.2％で251億3,000万米ドルに成長します。予測期間の成長は、罹患率の増加、新興市場、政府の支援政策、研究開発投資に起因しています。予測期間の主な動向には、精密医療、免疫療法と標的療法、個別化医療、臨床試験と医薬品パイプライン、併用療法、バイオマーカー主導型治療、遠隔医療と遠隔モニタリングなどが含まれます。

前立腺がん治療薬市場は、男性老年人口の増加によって大きく牽引されます。前立腺がんは60歳以上の男性が罹患することが多く、米国の政府機関であるACL（Administration for Community Living）が示すように、老人人口は2040年までに21.6％増加すると予測されています。米国がん協会の2022年1月の報告によると、前立腺がんの罹患率は高齢男性で高く、老年人口では10例中約6例が65歳以上の男性で診断されています。このように、高齢男性の人口増加は、前立腺がん治療薬市場の拡大を促進する重要な要因となっています。

がん罹患率の上昇は、前立腺がん治療薬市場の今後の成長の原動力になると予想されます。がんは、体内の異常細胞の無秩序な増殖と分裂を特徴とし、前立腺がん治療薬は、がん細胞の増殖を促進する特定の細胞変化を標的とする重要な役割を果たします。これは従来の化学療法やホルモン療法とは異なります。2023年1月、米国がん協会は、前立腺がんの新規患者数は約28万8,300人、この病気に関連する死亡者数は約3万4,700人と推定しています。男性の8人に1人が生涯のうちに前立腺がんと診断されると予測されています。その結果、がんの罹患率の増加が前立腺がん治療薬市場の重要な促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界前立腺がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の前立腺がん治療薬市場：成長率分析
• 世界の前立腺がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の前立腺がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界前立腺がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の前立腺がん治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン感受性前立腺がん
• ホルモン抵抗性前立腺がん
• 世界の前立腺がん治療薬市場：セラピー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン療法
• 化学療法
• 免疫療法
• 標的療法
• 世界の前立腺がん治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の前立腺がん治療薬市場ホルモン感受性前立腺がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 早期前立腺がん
• 局所進行前立腺がん
• 転移性前立腺がん
• 世界の前立腺がん治療薬市場ホルモン抵抗性前立腺がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 去勢抵抗性前立腺がん（CRPC）
• 転移性去勢抵抗性前立腺がん（mCRPC）

第7章 地域別・国別分析

• 世界の前立腺がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の前立腺がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 前立腺がん治療薬市場：競合情勢
• 前立腺がん治療薬市場：企業プロファイル
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• F. Hoffmann-La Roche AG
• Abbott Laboratories
• Pfizer Inc.
• Novartis International AG
• F. Hoffmann-La Roche Ltd.
• Tolmar Inc.
• AbbVie Inc.
• Siemens Healthineers AG
• Genomic Health Inc.
• OPKO Health Inc.
• Siemens Healthcare GmbH
• MDxHealth SA
• Myriad Genetics Inc.
• Janssen Biotech Inc.
• Clovis Oncology Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 前立腺がん治療薬市場2029：新たな機会を提供する国
• 前立腺がん治療薬市場2029：新たな機会を提供するセグメント
• 前立腺がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Prostate cancer drugs are pharmaceuticals employed for both the prevention and treatment of prostate cancer. Prostate cancer is among the most prevalent malignancies, characterized by the uncontrolled proliferation of cells in the prostate gland of men, which is responsible for producing seminal fluid for nourishing and transporting sperm. Potential treatment options for prostate cancer encompass hormonal therapy, chemotherapy, immunotherapy, and targeted therapy.

The distinct categories of prostate cancer drugs revolve around hormone-sensitive prostate cancer and hormone-refractory prostate cancer. Hormone-refractory prostate cancer (HRPC) represents a form of prostate cancer that no longer responds to hormone therapy, even to more recent treatment approaches. Various therapeutic methods encompass hormonal therapy, chemotherapy, immunotherapy, and targeted therapy and are implemented across diverse healthcare sectors, including hospitals, clinics, and other medical facilities.

The prostate cancer drugs market research report is one of a series of new reports from The Business Research Company that provides prostate cancer drugs market statistics, including prostate cancer drugs industry global market size, regional shares, competitors with a prostate cancer drugs market share, detailed prostate cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer drugs industry. This prostate cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer drugs market size has grown strongly in recent years. It will grow from $18.53 billion in 2024 to $19.77 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to aging population, increased diagnoses, drug innovation, awareness and education, reimbursement and insurance.

The prostate cancer drugs market size is expected to see strong growth in the next few years. It will grow to $25.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growing incidence, emerging markets, supportive government policies, r&d investments. Major trends in the forecast period include precision medicine, immunotherapy and targeted therapies, personalized medicine, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring.

The prostate cancer drugs market is significantly driven by the increasing male geriatric population. Prostate cancer predominantly affects men aged above 60, and the geriatric population is anticipated to grow by 21.6% by 2040, as indicated by the Administration for Community Living (ACL), a US-based government organization. Prostate cancer incidence is higher in older men, with approximately 6 out of 10 cases diagnosed in men aged 65 or older within the geriatric population, according to the American Cancer Society's January 2022 report. Thus, the growing population of elderly men is a key factor fueling the expansion of the prostate cancer drugs market.

The rising cancer incidence is expected to be a driving force behind the future growth of the prostate cancer drugs market. Cancer is characterized by the uncontrolled growth and division of abnormal cells in the body, and prostate cancer drugs play a crucial role in targeting specific cellular changes that promote cancer cell growth. This differs from traditional chemotherapy and hormone therapy. In January 2023, the American Cancer Society estimated approximately 288,300 new cases of prostate cancer and about 34,700 deaths related to the disease. One in eight men is projected to be diagnosed with prostate cancer during their lifetime. Consequently, the increasing incidence of cancer is a significant driver for the prostate cancer drugs market.

An emerging trend in the market is the adoption of combination therapy for the treatment of prostate cancer. This approach is particularly useful in cases where monotherapy proves ineffective. Market companies are increasingly investing in combination therapy, such as the use of XTANDI (enzalutamide) alongside androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer. This combination therapy has demonstrated a significant 71% reduction in the risk of metastasis or death compared to ADT alone. Similar combination therapies include the use of radiation therapy and ADT for men with recurrent prostate cancer and the use of the chemotherapy drug docetaxel (Taxotere) in conjunction with ADT for prostate cancer treatment.

Major companies in the prostate cancer drugs market are striving to introduce new products and gain approvals from regulatory agencies to maximize their market revenues. The process of drug development and approval is intricate and time-consuming, necessitating a thorough understanding of regulatory controls and marketing pathways to ensure safety and effectiveness. For instance, in June 2023, AstraZeneca PLC and Merck & Co. Inc. announced the approval of LYNPARZA (olaparib) Plus Abiraterone and Prednisone or Prednisolone for treating adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) by the United States Food and Drug Administration (USFDA). The approval was based on the significant improvements in radiographic progression-free survival (rPFS) and overall survival (OS) demonstrated by LYNPARZA plus abi/pred in comparison to abi/pred alone, as observed in the Phase 3 PROpel trial.

In March 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Ambrx Biopharma Inc. for an undisclosed sum. This acquisition enables Johnson & Johnson to advance the development of targeted oncology therapies by leveraging Ambrx's proprietary ADC technology, which integrates highly specific monoclonal antibodies with powerful chemotherapeutic agents. This innovative approach enhances the precision of cancer treatment, reducing common chemotherapy side effects and revolutionizing the treatment landscape for solid tumors, such as prostate cancer. Ambrx Biopharma Inc. is a biotechnology company based in the United States, specializing in the creation of groundbreaking therapies, including drugs for prostate cancer.

Major companies operating in the prostate cancer drugs market include Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, F. Hoffmann-La Roche AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., GlaxoSmithKline PLC, Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Biogen Inc., Celgene Corporation, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Agios Pharmaceuticals Inc., Exelixis Inc.

North America was the largest region in the prostate cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the prostate cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The prostate cancer drugs market consists of sales of Abiraterone Acetate, Apalutamide, and Bicalutamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hormone Sensitive Prostate Cancer; Hormone Refractory Prostate Cancer
• 2) By Therapy: Hormonal Therapy; Chemotherapy; Immunotherapy; Targeted Therapy
• 3) By End User: Hospitals; Clinics; Other End-Users
• Subsegments:
• 1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer; Locally Advanced Prostate Cancer; Metastatic Prostate Cancer
• 2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC); Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Companies Mentioned: Astellas Pharma Inc.; AstraZeneca PLC; Johnson & Johnson; Sanofi S.A.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Cancer Drugs Market Characteristics

3. Prostate Cancer Drugs Market Trends And Strategies

4. Prostate Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Prostate Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prostate Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prostate Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Prostate Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prostate Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prostate Cancer Drugs Total Addressable Market (TAM)

6. Prostate Cancer Drugs Market Segmentation

• 6.1. Global Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Sensitive Prostate Cancer
• Hormone Refractory Prostate Cancer
• 6.2. Global Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• 6.3. Global Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End-Users
• 6.4. Global Prostate Cancer Drugs Market, Sub-Segmentation Of Hormone Sensitive Prostate Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Stage Prostate Cancer
• Locally Advanced Prostate Cancer
• Metastatic Prostate Cancer
• 6.5. Global Prostate Cancer Drugs Market, Sub-Segmentation Of Hormone Refractory Prostate Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Castration-Resistant Prostate Cancer (CRPC)
• Metastatic Castration-Resistant Prostate Cancer (mCRPC)

7. Prostate Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Prostate Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prostate Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate Cancer Drugs Market

• 8.1. Asia-Pacific Prostate Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate Cancer Drugs Market

• 9.1. China Prostate Cancer Drugs Market Overview
• 9.2. China Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate Cancer Drugs Market

• 10.1. India Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate Cancer Drugs Market

• 11.1. Japan Prostate Cancer Drugs Market Overview
• 11.2. Japan Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate Cancer Drugs Market

• 12.1. Australia Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate Cancer Drugs Market

• 13.1. Indonesia Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate Cancer Drugs Market

• 14.1. South Korea Prostate Cancer Drugs Market Overview
• 14.2. South Korea Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate Cancer Drugs Market

• 15.1. Western Europe Prostate Cancer Drugs Market Overview
• 15.2. Western Europe Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate Cancer Drugs Market

• 16.1. UK Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate Cancer Drugs Market

• 17.1. Germany Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate Cancer Drugs Market

• 18.1. France Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate Cancer Drugs Market

• 19.1. Italy Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate Cancer Drugs Market

• 20.1. Spain Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate Cancer Drugs Market

• 21.1. Eastern Europe Prostate Cancer Drugs Market Overview
• 21.2. Eastern Europe Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate Cancer Drugs Market

• 22.1. Russia Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate Cancer Drugs Market

• 23.1. North America Prostate Cancer Drugs Market Overview
• 23.2. North America Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate Cancer Drugs Market

• 24.1. USA Prostate Cancer Drugs Market Overview
• 24.2. USA Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate Cancer Drugs Market

• 25.1. Canada Prostate Cancer Drugs Market Overview
• 25.2. Canada Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate Cancer Drugs Market

• 26.1. South America Prostate Cancer Drugs Market Overview
• 26.2. South America Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate Cancer Drugs Market

• 27.1. Brazil Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate Cancer Drugs Market

• 28.1. Middle East Prostate Cancer Drugs Market Overview
• 28.2. Middle East Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate Cancer Drugs Market

• 29.1. Africa Prostate Cancer Drugs Market Overview
• 29.2. Africa Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prostate Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Prostate Cancer Drugs Market Competitive Landscape
• 30.2. Prostate Cancer Drugs Market Company Profiles
  • 30.2.1. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Prostate Cancer Drugs Market Other Major And Innovative Companies

• 31.1. F. Hoffmann-La Roche AG
• 31.2. Abbott Laboratories
• 31.3. Pfizer Inc.
• 31.4. Novartis International AG
• 31.5. F. Hoffmann-La Roche Ltd.
• 31.6. Tolmar Inc.
• 31.7. AbbVie Inc.
• 31.8. Siemens Healthineers AG
• 31.9. Genomic Health Inc.
• 31.10. OPKO Health Inc.
• 31.11. Siemens Healthcare GmbH
• 31.12. MDxHealth SA
• 31.13. Myriad Genetics Inc.
• 31.14. Janssen Biotech Inc.
• 31.15. Clovis Oncology Inc.

32. Global Prostate Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate Cancer Drugs Market

34. Recent Developments In The Prostate Cancer Drugs Market

35. Prostate Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Prostate Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prostate Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prostate Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer